A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year | After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate,
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor,
Yearly HIV prevention injection 'Lenacapavir' shows promise in clinical trial
A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a clinical trial published in The Lancet journal. 'Lenacapavir' was developed by Gilead Sciences,
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Yearly HIV Injection Shows Promise in Prevention Efforts
A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is safe and has long-lasting effects for HIV prevention. While promising, the study's small sample size necessitates more research for broader conclusions.
Twice-Yearly Lenacapavir Gets Priority Review For HIV PrEP
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
El Mundo on MSN51m
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
‘Annual shot to prevent HIV proven safe’
The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...
The Lancet16h
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
Rolling Out12d
HIV breakthrough faces critical funding cuts
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
Daily Maverick on MSN5d
South Africa: The Global Fund Will Roll Out the Twice-Yearly Anti-HIV Jab - With or Without PEPFAR
The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...
Interesting Engineering on MSN10h
Revolutionary HIV injection could offer a full year of protection in just one dose
A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...
Annual jab for HIV protection passes trial hurdle
Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.
HIV prevention medication ‘could one day be a yearly jab’ – study suggests
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...